+91-8668442535

Psoriasis Treatment Market By Drug Class (TNF Inhibitors, Vitamin D Analogues, Interleukin Blockers, Topical Corticosteroids), By Type (Plaque Psoriasis, Guttate Psoriasis, Flexural Or Inverse Psoriasis, Psoriatic Arthritis) - Growth, Share, Opportunities & Competitive Analysis, 2015 – 2025

Psoriasis is a chronic, inflammatory, and painful skin disease; currently, there is no cure. The primary goal of treatment is to reduce inflammation and abnormal skin plaque formation. The psoriasis treatment market is rapidly growing due to growing prevalence, significant unmet needs, and promising pipeline molecules that would fuel the growth of the psoriasis treatment market worldwide.

The "Psoriasis Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall psoriasis treatment market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug class, type, and different geographical regions.

Geographically, the global psoriasis treatment market is studied for the following regional markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of LATAM
  • Middle East and Africa
  • GCC
  • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global psoriasis treatment market.

Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global psoriasis treatment market.

This report concludes with a company profiles section that highlights major information about the key players engaged in the global psoriasis treatment market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global psoriasis treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug class, the global psoriasis treatment market is segmented as follows:

  • Interleukin Blockers
  • Topical Corticosteroids
  • Tumor Necrosis Factor (TNF) Inhibitors
  • Vitamin D substitutes
  • Others

Psoriasis is a chronic, autoimmune, inflammatory skin disorder characterized by red patches of abnormal skin. Factors such as the increase in the prevalence of psoriasis and other skin disorders and the increase in treatment awareness are driving the growth of the psoriasis treatment market globally. The main goal of psoriasis treatment is to reduce inflammation and stop plaque formation.

For the treatment of psoriasis, medication is generally given by topical, systemic, or oral routes; along with medication, phototherapy alone or in combination with medication is widely accepted in the market. Biologics such as Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Secukinumab (Cosentyx), Ustekinumab (Stelara), and Taltz (ixekizumab) are widely used in the market, and newly approved biologics such as Siliq (brodalumab) and Tremfya (Guselkumab) are expected to drive significant market growth during the forecast period.

There are different types of medication used in the market; among these, interleukin blockers held the largest market share in the base year 2016 because interleukin blocker drugs such as ustekinumab, secukinumab, and ixekizumab have long-term safety with a lower risk of infection and malignancy. Because psoriasis is associated with inflammation, tumor necrosis factors such as certolizumab pegol, etanercept, adalimumab, infliximab, golimumab, the vitamin D analog calcipotriol, and topical corticosteroids are widely used on the market. Other medications, such as retinoids, calcineurin inhibitors, and cyclosporine, are used to reduce plaque formation.

Based on type, the global psoriasis treatment market is segmented as follows:

  • Plaque psoriasis
  • Guttate psoriasis
  • Flexural or inverse psoriasis
  • Psoriatic arthritis
  • Others

Psoriasis is a chronic, autoimmune, inflammatory skin disorder characterized by red patches of abnormal skin. Factors such as the increase in the incidence of psoriasis and other skin disorders, the increase in treatment awareness, and the wide availability of treatment medications are driving the growth of the psoriasis treatment market globally.

The main goal of psoriasis treatment is to reduce inflammation and stop plaque formation. The psoriasis treatment market is segmented on the basis of types, such as plaque, guttate, flexural or inverse, psoriatic arthritis, and other types of psoriasis. It is observed that plaque psoriasis is a major revenue-generating segment because plaque psoriasis is the most common form of psoriasis and affects 85%–90% of people with psoriasis; approximately 2%–3% of the population of the United States is affected by plaque psoriasis. There are different types of medications, such as vitamin D analogs, topical retinoids, and tazarotene, that are widely used in the market.

For the purpose of this study, the global psoriasis treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Psoriasis is a chronic, non-communicable, painful skin disease for which there is no cure and which has a great negative impact on patients' quality of life. It can occur at any age but is more common in older people. According to the International Federation of Psoriasis Associations (IFPA), about 3 percent of the world's population has some form of psoriasis. In the base year 2016, North America dominated the psoriasis treatment market. The United States is the largest revenue contributor due to the upsurge in funding by government agencies and private organizations in the healthcare system.

The higher cost of medication and the higher number of psoriasis patients are factors fueling the growth of the psoriasis treatment market. According to the Cleveland Clinic, there are about 150,000 new cases of psoriasis every year in the United States; approximately 2 percent of the U.S. population is affected by psoriasis. Europe is the second largest revenue-generating regional market for psoriasis treatment due to the higher number of psoriasis patients reported in some European regions, such as the Faroe Islands, where about 2.8% of the population is affected with psoriasis. It is observed that, currently, Asia Pacific holds the smallest market share due to factors such as the lowest incidence rate in some countries such as Japan, Australia, China, and India; also, the comparatively lower cost of medication may hinder the growth of the psoriasis treatment market in Asia Pacific.

Frequently Asked Question:

The market for Psoriasis Treatment Market is expected to reach USD$ 12.8 Bn in 2025.

The Psoriasis Treatment Market is expected to see significant CAGR growth over the coming years, at 5.4%.

The report is forecasted from 2015 -2025.

The base year of this report is 2014.

AbbVie Inc.,Amgen Inc.,AstraZeneca,Biogen. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jul 2017
Category:  Pharmaceuticals
Report ID:   58469
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support